CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Stock Down 5.0 %

CRSP stock traded down $2.52 during trading on Friday, reaching $47.91. 2,670,731 shares of the company’s stock were exchanged, compared to its average volume of 2,435,954. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $91.10. The company’s fifty day moving average price is $42.16 and its 200-day moving average price is $46.07. The firm has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lowered their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Barclays boosted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Finally, TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $74.40.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently modified their holdings of CRSP. Blue Trust Inc. lifted its holdings in shares of CRISPR Therapeutics by 158.7% in the third quarter. Blue Trust Inc. now owns 3,844 shares of the company’s stock valued at $181,000 after buying an additional 2,358 shares during the period. Eastern Bank acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at $70,000. International Assets Investment Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at $1,825,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of CRISPR Therapeutics by 15.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 40,568 shares of the company’s stock valued at $1,906,000 after buying an additional 5,567 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock valued at $146,000 after buying an additional 545 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.